ACT Genomics is here to help! If you have any questions or need assistance, please reach out by phone, email us or fill-in the form below. This form is solely for general information purposes and should not be seen as advice from a doctor. ACT Genomics cannot respond to questions concerning specific medical information or your personal medical condition.
ACT Genomics is a world-leading cancer solution provider. We offer precision medicine services in Taiwan, Singapore, Hong Kong, and Japan. We combine our expertise in tumor biology, cancer genomics, and bioinformatics to provide treatment guidelines for solid tumors, relapse, drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation. Through cutting-edge next-generation sequencing (NGS) platforms, bioinformatics analysis, and comprehensive service offerings, we seek to convert every cancer patient’s genetic information into actionable solutions.
ACT Genomics Taiwan
Our team comprises highly dedicated specialists in various domains, such as cancer biology, next-generation sequencing, bio- and medical informatics, who seek to exploit the power of genomics. Our company’s state-of-the-art technological capacity provides the possibility to convert cancer genomic information into precision diagnosis and personalized treatments. We look forward to collaborating with physicians and cancer patients to improve the quality of life of cancer patients and make cancer manageable.
We partner with the leading oncologists in cancer hospitals as well as cancer research institutes in Southeast Asia and beyond. Together, we aspire to transform the lives of cancer patients and turn their hope into reality.
ACT Genomics Singapore
We look forward to hearing from you .
ACT Genomics Hong Kong was established in January 2017 to meet the growing cancer needs in Hong Kong. The Next Generation Sequencing (NGS) laboratory at Hong Kong Science Park was opened in July 2019 to provide our cutting-edge services to the region.
In Hong Kong, there were 33,075 newly diagnosed cancer cases in 2017, which has increased by 2.8% annually according to The Hong Kong Cancer Registry. The five most-common forms of cancer in 2017 were colorectal cancer (17%), lung cancer (15.7%), breast cancer (13.3%), prostate cancer (6.8%), and liver cancer (5.5%).
We are a team of experts with years of experience in oncology, cancer genomics, and bioinformatics, and we share the goal to provide treatment guidance and disease monitoring with better precision to our cancer patients.
ACT Genomics Hong Kong
Sanomics Holdings Limited
We look forward to hearing from you.
ACT Genomics Japan was established in March 2017 and officially began a partnership with Canon Medical System Corporation in 2018. Through ACTMed, our joint venture in Japan, ACT Genomics and Canon Medical will continue to exploit cancer genomic testing to provide cancer treatment selection and disease monitoring with better precision for patients in Japan. We currently have a strong collaboration with prestigious universities in Japan to accelerate cancer research, with the shared vision of turning the tide in this battle against cancer.
.png){kind=logo}
More information about ACTmed: https://www.actmed.jp/
MC Diagnostics Ltd. (MCD), founded in 2006, is a specialist molecular diagnostic company based in the United Kingdom and has become a member of ACT Genomics Group in 2021. MCD provides expertise in the automation of multiplexed molecular assays as well as custom-designed image analysis and interpretation software.
MCD has designed, developed and manufactured the Automated Low-density Array System (“ALDAS”) and is currently providing proven clinical diagnostic assays in the fields of HLA typing and blood group diagnostics in Europe. Leveraging on the cutting-edge ALDAS, ACT Genomics and MCD are developing innovative genechip products addressing specific applications in the field of oncology. We are keen to bring to the market an effective and affordable cancer diagnostics testing tools with quick turnaround time and high sensitivity for the wellbeing of cancer patients around the world.
More information about MC Diagnostics
.png)
MC Diagnostics
Sanomics (Thailand) Limited